Mirodenafil
CAS 862189-95-5
Mirodenafil (CAS 862189-95-5) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 100 nM | 1 | - |
| cGMP-specific 3',5'-cyclic phosphodiesterase Enzyme |
IC50 | 9.469 | - | Homo sapiens |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Mirodenafil used for in pharmaceutical contexts?
Mirodenafil (CAS 862189-95-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Mirodenafil?
No adverse-event association or SIDER side-effect rows are rendered for Mirodenafil in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Mirodenafil also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Mirodenafil with EU status "permitted".
What clinical phase is Mirodenafil in?
Mirodenafil is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Mirodenafil?
Mirodenafil has 2 bioactivity rows in this page query. Rendered target entries include cGMP-specific 3',5'-cyclic phosphodiesterase.